COMPACT Phase III Clinical Trial Results
218 views · Published 23 March 2017 · 2:41 · Indexed 23 October 2026
Channel: MultiVu · 2017 · Howto & Style
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE. To view the multimedia release go to: https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
More from this channel
-
2:24
Nespresso by KitchenAid
-
0:53
Best Skincare & Makeup Reviews
-
5:01
AARP Magazine With Sheryl Crow and Melissa Etheridge
-
1:57
Concentrix Flagship Delivery Center
-
1:09
Casino Gaming’s Economic Impact
-
2:00
Anchor it and Protect a Child
-
2:42
The PowerHaul Locomotive Platform
-
0:31
New PSA aims to bridge opportunity divide